$VEEV

Veeva Rises on Sales and Margin Gains, Guidance Raise

Veeva Systems (VEEV) reported Q2 fiscal 2027 revenue of $928M, up 18% YoY, with non-GAAP operating income of $415.9M. The company raised guidance to $3.687B in revenue and $9.21 in non-GAAP EPS. VEEV shares have risen 25% YTD, supported by strong institutional demand and robust fundamentals, including 3-year sales and EPS growth rates of 14.1% and 21.6%, respectively.

Original reporting
Published Sep 3, 2026, 8:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Veeva Rises on Sales and Margin Gains, Guidance Raise — source image
Decision brief

The 30-second read

$VEEVBullishMed
01

Why it matters

The earnings beat and raised guidance reinforce Veeva's growth narrative, likely attracting more institutional buying.

02

Market read

Earnings and guidance lift for a large‑cap SaaS player can influence sector sentiment and related stocks.

03

What to watch

Potential headwinds from regulatory changes or slower adoption of new modules.

Relevance 8/10Novelty 8/10Timing: after‑hours

Background

Veeva Systems provides cloud solutions for life‑sciences companies, emphasizing compliance and data integrity.

Company-level read

Ticker impact

$VEEVBullishHigh confidence
Context

Veeva reported Q2 FY2027 revenue of $928M (18% YoY) and raised FY2027 guidance to $3.687B revenue and $9.21 non‑GAAP EPS.

Expected impact

Potential upside of 5‑10% as investors price in higher guidance.

Evidence & confidence

Guidance lift and margin expansion are material for a large‑cap SaaS provider.

Market effects

Positive signal for the broader life‑sciences SaaS sector.

U.S. tech and healthcare markets may see modest gains.

Limited to investors tracking cloud‑based health‑tech firms.

Counterpoint

If guidance proves overly optimistic, a correction could follow.

Key entities

  • Veeva Systems Inc.

    Provider of cloud‑based software for the life‑sciences industry.

Related articles

$VEEVHighAI 8/10

Watch Veeva, CrowdStrike, and More

Veeva Systems (VEEV) reported Q2 non-GAAP EPS of $2.35, revenue growth of 17.6% Y/Y to $928M, and raised its Q3 revenue forecast. CrowdStrike (CRWD) posted 25.6% Y/Y revenue growth to $1.47B. Dycom Industries (DY) fell 11.6% despite 45.6% Y/Y revenue growth to $2.01B due to segment pressures and higher costs.

$VEEVHighAI 8/10

Veeva (VEEV) Q2 2027 Earnings Call Transcript

Veeva Systems (VEEV) reported Q2 2027 revenues of $928.0 million, up 18% YoY, driven by growth in commercial and R&D segments. Subscription revenues rose 16% to $766.8 million. Non-GAAP operating income was $415.9 million, with a 44.8% margin. The company raised FY 2027 revenue guidance to $3.682B-$3.687B and EPS guidance to $9.21. Management highlighted strong adoption of Vault CRM and Data Cloud solutions, with 12 top 20 biopharmas committed to Vault CRM. Risks include the launch of the new Fa

$VEEVHighAI 9/10

VEEV Looks 5.0% Undervalued on GF Value™

Veeva Systems (VEEV) shares rose 9% after-hours on August 30, 2026, following stronger-than-expected Q2 results and raised full-year guidance. GF Value™ estimates VEEV as 5.0% undervalued at $276.69, with a GF Score™ of 95. Subscription revenues grew 16% to $766.8M. Insiders sold $18.1M in shares, while 8 gurus hold the stock, with 7 adding positions.

$NVDAHighAI 9/10

Markets News, Aug. 27, 2026: Nvidia Stock Powers Higher After Earnings, Driving Tech Gains; Nasdaq Closes Sharply Higher

Nvidia (NVDA) reported strong Q2 earnings and raised Q3 revenue guidance to $108B, driving its stock up 9% and boosting tech sector gains. Nasdaq, S&P 500, and Dow closed higher. Other notable movers include Okta (OKTA) +29%, Salesforce (CRM) +23%, and CrowdStrike (CRWD) +20%. Corporate profits surged $400B in Q2, partly due to $71B in tariff refunds.